Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.

@article{Vardy2009EffectsOS,
  title={Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.},
  author={Michael D. Vardy and H David Mitcheson and T H Samuels and John D Wegenke and Sergio Forero-Schwanhaeuser and Thomas S. Marshall and Weizhong He},
  journal={International journal of clinical practice},
  year={2009},
  volume={63 12},
  pages={1702-14}
}
AIM The aim of this study was to evaluate the efficacy of solifenacin on symptom bother using the Overactive Bladder Questionnaire (OAB-q). METHODS In VIBRANT, a double-blind, US-based trial, patients with OAB for > or = 3 months received flexibly dosed solifenacin or placebo for 12 weeks. At baseline and 4-week intervals, patients completed the OAB-q [symptom bother and health-related quality of life (HRQL) scales] and 3-day bladder diaries; other patient-reported outcome measures were also… CONTINUE READING